Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 6 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 6 of 10.)

DateHeadlineEventSource5-minTo close
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myelomaPress releasePR Newswire+0.27%-0.01%
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology UnitPress releaseBusiness Wire+0.22%+0.40%
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy FailsPress releaseBusiness Wire-0.17%+1.11%
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.09%+0.88%
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasisPress releasePR Newswire-0.01%-0.77%
Johnson & Johnson expands efforts to champion the nursing workforce globallyPress releaseBusiness Wire+0.25%-0.10%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR+0.25%-0.10%
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two yearsPress releasePR Newswire-0.84%-1.07%
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeksPress releasePR Newswire-0.84%-1.07%
Form 8-K JOHNSON & JOHNSON For: Apr 24SEC filing · Form 8-KSEC EDGAR-0.69%-0.35%
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.93%-1.07%
Products That Count Announces Winners of the 2025 Q1 Product AwardsPress releasePR Web-0.04%+0.42%
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions ConferencePress releaseBusiness Wire-0.19%+0.30%
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBCPress releasePR Newswire-0.33%-0.10%
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancerPress releasePR Newswire-0.33%-0.10%
Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung CancerPress releasePR Web-0.33%-0.10%
Form 10-Q JOHNSON & JOHNSON For: Mar 30SEC filing · Form 10-QSEC EDGAR-0.91%-0.56%
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUAPress releasePR Newswire-0.26%-0.69%
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025Press releasePR Web-0.25%-0.66%
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire+1.46%+2.15%
Form 8-K JOHNSON & JOHNSON For: Apr 15SEC filing · Form 8-KSEC EDGAR-0.82%-1.72%
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%Press releaseBusiness Wire-0.82%-1.72%
Johnson & Johnson Reports Q1 2025 ResultsPress releaseBusiness Wire-0.82%-1.72%
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pillPress releasePR Newswire-0.69%-1.12%
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)Press releasePR Newswire-1.08%-2.28%
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare ConferencePress releaseBusiness Wire-1.08%-2.28%
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritisPress releasePR Newswire-0.39%-3.97%
Form 8-K JOHNSON & JOHNSON For: Mar 31SEC filing · Form 8-KSEC EDGAR-0.39%-3.97%
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience LeadershipPress releaseBusiness Wire+0.11%+0.69%
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial CourtsPress releaseBusiness Wire-1.05%-5.16%
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular AcquisitionPress releaseBusiness Wire+0.11%+0.69%
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc ClaimsPress releaseBusiness Wire-1.05%-5.16%
Med One Announces the Hiring of Sheri Thomas as Chief Financial OfficerPress releasePR Web+0.14%+0.15%
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.04%+0.32%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.08%+0.28%
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four YearsPress releaseBusiness Wire+0.12%+0.39%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025Press releasePR Newswire-0.10%+0.01%
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's diseasePress releasePR Newswire+0.12%+0.39%
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designationPress releasePR Newswire+0.02%+0.50%
Form ARS JOHNSON & JOHNSON For: Dec 29SEC filing · Form ARSSEC EDGAR-0.34%-0.54%
Form DEF 14A JOHNSON & JOHNSON For: Mar 12SEC filing · Form DEFSEC EDGAR-0.34%-0.54%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-0.34%-0.54%
Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerPress releaseCanada Newswire+1.25%+0.13%
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patientsPress releasePR Newswire+1.25%+0.13%
Six Dean Omar Branham Shirley Partners Honored for Representation of PlaintiffsPress releaseBusiness Wire-0.19%-0.80%
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasisPress releasePR Newswire+1.25%+0.13%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire+0.22%+0.42%
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor RelationsPress releaseBusiness Wire+0.73%+0.37%
Form CERT JOHNSON & JOHNSONSEC filing · Form CERTSEC EDGAR+0.09%+0.99%
Form 8-A12B JOHNSON & JOHNSONSEC filing · Form 8-A12BSEC EDGAR+0.05%+0.88%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground